hello world!
A global leader in pharmaceuticals was looking to pilot an interventional study in major depressive disorder (MDD) using a Direct-to-Patient Site model, in parallel to their Phase IIb trial.
Learn how Science 37 helped this sponsor expanded reach beyond the confines of traditional sites, outperforming traditional recruitment methods more than 20:1—potentially saving up to four months on study timeline.
